Uni-Bio Science Group Limited: 2018 Annual Results
Enhanced Market Penetration of Core Marketed Products Pipeline Products Witnessed a Steady Progress to Launch Commencement of CMO Service to…
Pharmaceuticals, Biotechnology and Life Sciences
Enhanced Market Penetration of Core Marketed Products Pipeline Products Witnessed a Steady Progress to Launch Commencement of CMO Service to…
Alvogen licensed to sell volume-limited amounts of generic lenalidomide in the U.S. beginning on a confidential date after the March…
DUBLIN–(BUSINESS WIRE)–The “Global Anticoagulants Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,…
Bristol-Myers Squibb Urges Shareholders to Vote “FOR” the Merger-Related Proposals on the WHITE Proxy Card Today NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, and Definiens,…
With a website unveiled at the Innovation Expo and a presentation by its Regulatory Affairs Director, new DKT International program…
New molecular platform to access intracellular targets across a broad range of tumor cell types Opens up new range of…
Destiny Pharma has picked MedPharm to develop new topical formulations of its novel XF-platform compounds, new treatments for dermal and ocular infections which are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR).
The CHMP adopted two positive opinions recommending European Commission approval of: REVLIMID in combination with bortezomib and dexamethasone (RVd) in…
DUBLIN–(BUSINESS WIRE)–The “Metagenomics Market to 2027 – Global Analysis and Forecasts by Product, Application and Geography” report has been added…